Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PPP3CA divergent transcript, most accurately named Splicing Regulatory Small Protein (SRSP), is the product of an lncRNA (LOC90024, also called PPP3CA-DT in some systems). SRSP is a 130-amino acid microprotein that regulates pre-mRNA splicing, interacting with splicing regulators (particularly SRSF3) to promote inclusion of specific exons in target genes (notably the transcription factor Sp4). Upregulation of SRSP in cancer cells drives splicing isoforms that enhance tumorigenesis, especially in colorectal cancer, and high expression has been proposed as a poor-prognosis biomarker for this disease. SRSP is mechanistically distinct from the protein phosphatase family PPP3CA (calcineurin A alpha): the term "divergent transcript" simply refers to its genomic location, not functional homology. There are currently no therapeutics directly targeting SRSP, but its activity highlights the role of lncRNA-encoded microproteins as new classes of therapeutic targets and biomarkers.
Drugs (if developed) would likely inhibit protein-protein interaction, RNA/protein expression, or splicing modulation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Splicing Regulatory Small Protein (SRSP).